ACHV News and Press, Achieve Life Sciences Inc. From 09/03/25

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decades ...

SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessatio...

2025-08-08 10:12:17 ET Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call August 7, 2025 8:30 A.M. ET Company Participants Cindy Jacobs - Former President & Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark K. Oki - Chief Financial Offic...

2025-08-07 07:33:14 ET More on Achieve Life Sciences Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk Achieve Life Sciences, ...

SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

Achieve Life Sciences Inc. (ACHV) is expected to report $-0.37 for Q2 2025

2025-08-06 18:00:16 ET Major earnings expected before the bell on Thursday include: Viatris ( VTRS ) Eli Lilly and Company ( LLY ) ConocoPhillips ( COP ) Datadog ( DDOG ) Warner Bros. Discovery ( WBD ) Read the full article on Seeking Alpha ...

2025-08-06 11:38:43 ET More on Achieve Life Sciences Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk Achieve Life Sciences, ...

SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation...